Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Depreciation and Depletion: 2024-2025

Historic Depreciation and Depletion for UNITED THERAPEUTICS (UTHR) over the last 2 years, with Sep 2025 value amounting to $21.5 million.

  • UNITED THERAPEUTICS's Depreciation and Depletion rose 14.36% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.4 million, marking a year-over-year change of. This contributed to the annual value of $71.6 million for FY2024, which is 35.35% up from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Depreciation and Depletion of $21.5 million as of Q3 2025, which was up 2.87% from $20.9 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's Depreciation and Depletion's 5-year high stood at $21.5 million during Q3 2025, with a 5-year trough of $14.8 million in Q1 2024.
  • Over the past 2 years, UNITED THERAPEUTICS's median Depreciation and Depletion value was $19.4 million (recorded in 2024), while the average stood at $19.1 million.
  • Data for UNITED THERAPEUTICS's Depreciation and Depletion shows a peak YoY skyrocketed of 32.43% (in 2025) over the last 5 years.
  • UNITED THERAPEUTICS's Depreciation and Depletion (Quarterly) stood at $19.4 million in 2024, then grew by 14.36% to $21.5 million in 2025.
  • Its Depreciation and Depletion was $21.5 million in Q3 2025, compared to $20.9 million in Q2 2025 and $19.6 million in Q1 2025.